List of excluded cost-effectiveness studies with reason

Karoline Freeman; Martin Connock; Peter Auguste; Sian Taylor-Phillips; Hema Mistry; Deepson Shyangdan; Rachel Court; Ramesh Arasaradnam; Paul Sutcliffe; Aileen Clarke

Appendix 13List of excluded cost-effectiveness studies with reason

Publication Details

TABLE 60

List of excluded studies from the literature review

Publication Details

Copyright

Copyright © Queen’s Printer and Controller of HMSO 2016. This work was produced by Freeman et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Included under terms of UK Non-commercial Government License.

Publisher

NIHR Journals Library, Southampton (UK)

NLM Citation

Freeman K, Connock M, Auguste P, et al. Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [LISA-TRACKER® enzyme-linked immunosorbent assay (ELISA) kits, TNF-α-Blocker ELISA kits and Promonitor® ELISA kits] versus standard care in patients with Crohn’s disease: systematic reviews and economic modelling. Southampton (UK): NIHR Journals Library; 2016 Nov. (Health Technology Assessment, No. 20.83.) Appendix 13, List of excluded cost-effectiveness studies with reason.

TABLE 60

List of excluded studies from the literature review

Reference	Reason(s) for exclusion
Blackhouse G, Assasi N, Xie F, Marshall J, Irvine EJ, Gaebel K, et al. Canadian cost–utility analysis of initiation and maintenance treatment with anti-TNF-alpha drugs for refractory Crohn’s disease. J Crohns Colitis 2012;6:77–85	No testing kits used to monitor anti-TNF-α or antibodies to anti-TNF-α levels
Bodger K, Kikuchi T, Hughes D. Cost-effectiveness of biological therapy for Crohn’s disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment Pharmacol Ther 2009;30:265–74	No testing kits used to monitor anti-TNF-α or antibodies to anti-TNF-α levels
Buchanan J, Wordsworth S, Ahmad T, Perrin A, Vermeire S, Sans M, et al. Managing the long term care of inflammatory bowel disease patients: the cost to European health care providers. J Crohns Colitis 2011;5:301–16	No testing kits used to monitor anti-TNF-α or antibodies to anti-TNF-α levels
Dretzke J, Edlin R, Round J, Connock M, Hulme C, Czeczot J, et al. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn’s disease. Health Technol Assess 2011;15(6)	No testing kits used to monitor anti-TNF-α or antibodies to anti-TNF-α levels
Kaplan GG, Hur C, Korzenik J, Sands BE. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn’s disease: a cost-effectiveness analysis. Aliment Pharmacol Ther 2007;26:1509–20	No testing kits used to monitor anti-TNF-α or antibodies to anti-TNF-α levels